O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate → N-[(2R)-2-({[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}amino)-2-phenylacetyl]-L-alanine
Reaction equation
FC1C=CC(N2[C:11](=[O:12])[C@H:10]([S:13][CH2:14][C:15]([C:17]3[CH:22]=[CH:21][C:20]([F:23])=[CH:19][CH:18]=3)=[O:16])[C@H:9]2[C:24]2[CH:44]=[CH:43][C:27]([O:28][CH2:29][C:30]([NH:32][C@H:33]([C:37]3[CH:42]=[CH:41][CH:40]=[CH:39][CH:38]=3)[C:34](O)=[O:35])=[O:31])=[CH:26][CH:25]=2)=CC=1.Cl.[NH2:46][C@H:47]([C:49]([O:51]C(C)(C)C)=[O:50])[CH3:48].CN(C(ON1N=[N:71][C:66]2[CH:67]=[CH:68][CH:69]=[CH:70][C:65]1=2)=[N+](C)C)C.[B-](F)(F)(F)[F:74]>C(Cl)Cl>[F:74][C:69]1[CH:70]=[CH:65][C:66]([N:71]2[C:11](=[O:12])[C@H:10]([S:13][CH2:14][CH:15]([C:17]3[CH:22]=[CH:21][C:20]([F:23])=[CH:19][CH:18]=3)[OH:16])[C@H:9]2[C:24]2[CH:44]=[CH:43][C:27]([O:28][CH2:29][C:30]([NH:32][C@H:33]([C:37]3[CH:42]=[CH:41][CH:40]=[CH:39][CH:38]=3)[C:34]([NH:46][C@H:47]([C:49]([OH:51])=[O:50])[CH3:48])=[O:35])=[O:31])=[CH:26][CH:25]=2)=[CH:67][CH:68]=1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
(2R)-({[4-((2R,3R)-1-(4-Fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}amino)(phenyl)acetic acid (0.040 g, 0.065 mmol) was dissolved in CH2Cl2 (5 ml). tert-Butyl L-alaninate hydrochloride (0.014 g, 0.078 mmol) and N-methyl-morphiline (0.020 g, 0.195 mmol) were added. After 5 minutes TBTU (0.027 g, 0.084 mmol) was added. The reaction was allowed to stir for 1 h after which the resulting tert-butyl ester was purified by chromatography on silica gel and eluted with EtOAc/CH2Cl2 25/75. Pure fractions were concentrated and dissolved in CH2Cl2 (4 ml) and trifluoroacetic acid (0.5 ml). After 1.5 h at room temperature, full conversion to the corresponding acid was obtained. The reaction mixture was concentrated and the residue of TFA was removed by co-evaporation with toluene (3 ml). The crude acid was dissolved in MeOH (3 ml) and NaBH4-(0.010 g, 0.260 mmol) was added. Full conversion to the corresponding alcohol was obtained after 5 minutes. The reaction was quenched by the addition of 0.1M NH4OAc buffer (1 ml). The mixture was concentrated and the residue was purified by preparative HPLC using a gradient of 20-50% CH3CN in 0.1M NH4OAc buffer as mobile phase. Freeze-drying afforded the title compound (0.020 g, 45%) as a colourless solid. M/z: 688.4 (M−1). 1H NMR [(CD3)2SO), 400 MH] δ 2.30-2.35 (m, 3H), 2.86-2.94 (m, 2H), 3.15-3.31 (m, 1H), 4.26-4.28 (m, 1H), 4.59 (d, 1H), 4.64 (d, 1H), 4.70-4.76 (m, 1H), 5.04-5.07 (m, 1H), 5.46 (d, 1H), 6.94-7.36 (m, 17H), 8.43-8.55 (m, 2H).
Workup
- customwas purified by chromatography on silica gel
- washeluted with EtOAc/CH2Cl2 25/75
- concentrationPure fractions were concentrated
- dissolutiondissolved in CH2Cl2 (4 ml)
- customfull conversion to the corresponding acid was obtained
- concentrationThe reaction mixture was concentrated
- customthe residue of TFA was removed by co-evaporation with toluene (3 ml)
- dissolutionThe crude acid was dissolved in MeOH (3 ml)
Sources & evidence
- ORD record
- ord-24d1dc833268483990652305a3a5c457
- Source dataset
- uspto-grants-2011_01
- Patent number
- US07871998B2
Reaction notes
Loading…